On October 15, 2021, the FDA approved Boehringer Ingelheim’s Cyltezo® (adalimumab-adbm) as interchangeable with AbbVie’s Humira® (adalimumab) for many of Humira’s approved indications.  As an interchangeable, Cyltezo can be automatically substituted for Humira at the pharmacy, subject to individual state laws.  Grant of interchangeability status was based on the phase III VOLTAIRE-X study, which evaluated switching patients with moderate-to-severe chronic plaque psoriasis between Cyltezo and Humira and back again, and found that those who switched had similar clinical outcomes in terms of safety, efficacy, pharmacokinetics, and immunogenicity to those who did not switch.

Cyltezo was initially approved as a U.S. biosimilar in August 2017, but it, along with the five other approved Humira biosimilars, has not yet launched.  Under a settlement agreement between AbbVie and Boehringer Ingelheim, Cyltezo can launch in the U.S. as of July 1, 2023.  According to the other settlement agreements, the soonest a Humira biosimilar will launch in the U.S. is Amgen’s Amjevita™ (adalimumab-atto) on January 31, 2023.

Cyltezo is the second drug to be granted interchangeable status in the U.S., following Viatris and Biocon’s Semglee® (insulin glargine-yfgn), which was approved as an interchangeable biosimilar to Sanofi’s Lantus® (insulin glargine) in July 2021. Cyltezo is the first monoclonal antibody to achieve interchangeable status in the U.S.

While finally having a biosimilar receive interchangeability status for one of the highest grossing drugs in the U.S. is very encouraging for patients, Cyltezo is approved as a low-concentration adalimumab (40mg/0.8mL, 20mg/0.4mL dosage strength), usage of which accounts for only about 10% of total adalimumab usage.  Therefore, only a small portion of patients will likely see the benefit of the lower cost of the interchangeable once it launches.

Currently, there is one pending aBLA for a high-concentration (100mg/mL) Humira biosimilar, AVT02, filed by AlvotechAlvotech also plans to seek an interchangeability designation for AVT02 based on results from its switching study AVT02-GL-302. AbbVie and Alvotech are involved in three pending litigations (Case Nos. 1:21-cv-02899 (N.D. Ill.), 1:21-cv-00589 (E.D. Va.), and 1:21-cv-02258 (N.D. Ill.)), and while Alvotech has stated it will launch its biosimilar at-risk, it has agreed not to launch until after a district court decision in these cases, which is slated for the end of October 2022.


    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website ( Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website ( Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.


    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates